Federico Comoglio

7PUBLICATIONS
37CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular medicineEpigenetics (incl. genome methylation and epigenomics)Haematological tumoursMedical devices
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 08, 2021
SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma.

Anne C Wilke, Carmen Doebele, Alena Zindel

|Aug 04, 2019
Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML.

Thomas Oellerich, Constanze Schneider, Dominique Thomas

|Feb 13, 2018
Thrombopoietin signaling to chromatin elicits rapid and pervasive epigenome remodeling within poised chromatin architectures.

Federico Comoglio, Hyun Jung Park, Stefan Schoenfelder

|Sep 14, 2017
Mbd3/NuRD controls lymphoid cell fate and inhibits tumorigenesis by repressing a B cell transcriptional program.

Stephen J Loughran, Federico Comoglio, Fiona K Hamey

|Apr 25, 2017
Stable Polycomb-dependent transgenerational inheritance of chromatin states in Drosophila.

Filippo Ciabrelli, Federico Comoglio, Simon Fellous

|Jan 09, 2017
HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling.

Roland Walter, Kuan-Ting Pan, Carmen Doebele

Pageof 2